FDA Rejects KRYSTEXXA As A Treatment For Chronic Gout

Savient Pharmaceuticals (SVNT) announced that it has received a complete response letter from the U.S. Food and Drug Administration stating that the FDA cannot at this time approve the Company's application for KRYSTEXXA as a treatment for chronic gout in patients refractory to conventional therapy.
Market News Video

Tags: Approval, Chronic Gout, Savient Pharmaceuticals, KRYSTEXXA